Literature DB >> 3182468

The comparative in-vitro activity of ofloxacin.

R N Grüneberg1, D Felmingham, M D O'Hare, M J Robbins, K Perry, R A Wall, G L Ridgway.   

Abstract

The antibacterial activity of ofloxacin, a new fluoroquinolone, was evaluated against a wide range of clinical bacterial isolates and compared with that of nalidixic acid, norfloxacin, enoxacin, pefloxacin and ciprofloxacin by determination of minimum inhibitory concentrations (MICs). Ofloxacin was very active against nalidixic acid-susceptible isolates of the Enterobacteriaceae (MIC less than or equal to 0.12 mg/l) and was also active against strains resistant to nalidixic acid (MIC less than or equal to 2 mg/l). The activity was similar to norfloxacin, enoxacin and pefloxacin but some four-fold less than that of ciprofloxacin. All of the fluoroquinolones were highly active against Vibrio cholerae (MIC less than or equal to 0.015 mg/l), V. parahaemolyticus (MIC less than or equal to 0.12 mg/l) Aeromonas hydrophila (MIC less than or equal to 0.03 mg/l), Plesiomonas shigelloides (MIC less than or equal to 0.015 mg/l), Campylobacter jejuni (MIC less than or equal to 0.5 mg/l), Neisseria spp., Haemophilus influenzae, H. ducreyi, Bordetella pertussis and Legionella pneumophila (MIC less than or equal to 0.06 mg/l for all species). Ofloxacin, ciprofloxacin and pefloxacin (MIC less than or equal to 1, 2 and 2 mg/l, respectively) showed similar activity against Staphylococcus spp. and were somewhat more active than enoxacin (MIC less than or equal to 4 mg/l) and norfloxacin (MIC less than or equal to 8 mg/l). Ofloxacin was moderately active against beta-haemolytic Streptococcus spp. (MIC less than or equal to 2 mg/l), Corynebacterium diphtheriae (MIC less than or equal to 1 mg/l) and Cory. jeikeium (MIC less than or equal to 2 mg/l) and somewhat less active against alpha- and non-haemolytic Streptococcus spp., Str. pneumoniae and Listeria monocytogenes (MIC less than or equal to 4 mg/l for all species) and Str. faecalis (MIC less than or equal to 8 mg/l). The activity of ofloxacin, against these species, was similar to ciprofloxacin and four to eight times greater than norfloxacin, enoxacin and pefloxacin. Ofloxacin, and all of the fluoroquinolones, were less active against anaerobic than aerobic bacteria. Clostridium perfringens (MIC less than or equal to 1 mg/l) was more susceptible to ofloxacin than were other anaerobic species and Cl. difficile (MIC less than or equal to 16 mg/l) was more resistant. Ofloxacin was the most active compound tested against Chlamydia trachomatis SA2f (MIC less than or equal to 0.5 mg/l) with only ciprofloxacin (MIC less than or equal to 1 mg/l) approaching similar activity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182468     DOI: 10.1093/jac/22.supplement_c.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora.

Authors:  J P Leeming; J P Diamond; R Trigg; L White; H B Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 3.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 4.  Quinolones in sexually transmitted diseases.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 7.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

8.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

9.  Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.

Authors:  Shuyu Xie; Luyan Zhu; Zhao Dong; Yan Wang; Xiaofang Wang; WenZhong Zhou
Journal:  Int J Nanomedicine       Date:  2011-03-15

10.  Quinolones for the treatment of Neisseria gonorrhoeae and Chlamydia trachomatis.

Authors:  S Faro
Journal:  Infect Dis Obstet Gynecol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.